Molecular Diagnostics News and Research

RSS

Merck, QIAGEN to collaborate to increase access to HPV vaccination and HPV DNA testing in developing countries

Merck & Co., Inc. and QIAGEN N.V. today announced their intent to collaborate on a new program to increase access to HPV vaccination and HPV DNA testing in some of the most resource-poor areas of the world.

From QIAGEN Manchester Limited 24 Sep 2009

Primeradx raises funds for commercialization of their technology

PrimeraDx, Inc., a privately held molecular diagnostics company, announced today that it has closed on its $20 million Series C financing. The financing was led by CHL Medical Partners and also included significant participation by many of the Company’s existing investors; Abingworth, InterWest Partners, Malaysian Technology Development Corporation, MPM Capital, Burrill & Company and the Invus Group.

21 Sep 2009

Health Discovery Corporation appoints new COO

Health Discovery Corporation, a personalized medicine company specializing in molecular diagnostics including gene-based testing, as well as computer assisted diagnostics in digital pathology and radiology, announced that former Deputy FDA Commissioner John A. Norris has been appointed as Chief Operating Officer (COO) of the Company.

19 Sep 2009

Targeted Molecular Diagnostics to offer digital pathology services in Beijing

Targeted Molecular Diagnostics (TMD), a Quintiles Central Laboratory, announced today the availability of digital pathology services in Beijing, China. The services add to Quintiles offerings used in the development of therapies to treat the world’s most pressing health issues, including cancer.

15 Sep 2009

Quest Diagnostics' OVA1 ovarian cancer test cleared by the FDA

The U.S. Food and Drug Administration (FDA) today cleared the OVA1(TM) Test, the first blood test that, prior to surgery, can help physicians determine if a woman is at risk for a malignant pelvic mass. OVA1 is the first FDA-cleared laboratory test that can indicate the likelihood of ovarian cancer with high sensitivity prior to biopsy or exploratory surgery, even if radiological test results fail to indicate malignancy.

From Quest Diagnostics 14 Sep 2009

Vitapath Genetics closes $6 million series A round of funding

VitaPath Genetics, a molecular diagnostics company, announced today that it has closed a $6 million series A round of funding led by MDV-Mohr Davidow Ventures. VitaPath was originally seeded by X/Seed Capital, which also co-invested in the Series A. Concurrent with the financing MDV's Michael Goldberg and X/Seed's Michael Borrus took seats on the company's board.

11 Sep 2009

QIAGEN's new QIAsafe DNA blood products launched

Biomatrica, Inc. and QIAGEN announce the launch of QIAGEN's new QIAsafe DNA Blood Products, the first dry blood storage available on a matrix based on Biomatrica's innovative SampleMatrix(R) technology.

From QIAGEN Manchester Limited 10 Sep 2009

Second-quarter fiscal 2009 results announced by Rosetta Genomics

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, today reported financial results for the three and six months ended June 30, 2009.

9 Sep 2009

Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics’ three currently available diagnostic tests.

8 Sep 2009

New H1N1 Influenza detection test used to diagnose Australia's first swine flu victim

When the first cases of H1N1 Influenza (swine flu) were reported in Mexico in April, UQ researchers got to work developing a test to diagnose the virus.

4 Sep 2009

FDA approves new xTAG Cystic Fibrosis 39 Kit v2 from Luminex

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new cystic fibrosis (CF) test: the xTAG® Cystic Fibrosis 39 Kit v2.

From Thermo Fisher Scientific Inc. 4 Sep 2009

New Technology Showcase highlighting life science technologies to be featured

LifeScience Alley announced today that eight life science organizations from around the United States and Canada will be exhibiting cutting-edge technologies at the association’s Annual Conference on Dec. 9 as part of the New Technology Showcase.

3 Sep 2009

Molecular pathology laboratories gear up for swift swine flu detection

Dr. Jan Nowak, President of the Association for Molecular Pathology presented public comments today at the Clinical Laboratory Improvement Advisory Committee meeting.

3 Sep 2009

Danaher to acquire mass spectrometry business from Life Technologies Corporation

Life Technologies Corporation (NASDAQ:LIFE) today announced it has signed a definitive agreement to sell its ownership stake in its mass spectrometry business, operated as a joint venture, to Danaher Corporation (NYSE:DHR) for $450 million in cash. Danaher has also signed an agreement to acquire Life Technologies’ joint venture partner in the mass spectrometry business, MDS Analytical Technologies, a division of MDS Inc. (NYSE:MDZ). The transaction is expected to close in the fourth quarter of 2009.

From Danaher 2 Sep 2009

MultiGEN Diagnostics launches new technology for clinical testing in molecular diagnostics

San Diego-based MultiGEN Diagnostics Inc. has launched a novel multi-target DNA sequencing technology (MultiGEN) for a wide range of clinical testing in molecular diagnostics.

1 Sep 2009

Abbott to partner with Pfizer to develop a companion diagnostic test for non-small cell lung cancer

Abbott announced today that it has entered into an agreement with Pfizer Inc to develop a molecular diagnostic test intended to screen non-small cell lung cancer (NSCLC) tumors for the presence of gene rearrangements.

28 Aug 2009

Novel methodology developed to extract microRNAs from cancer tissues

Researchers led by Dr. Soheil Dadras at the Stanford University Medical Center have developed a novel methodology to extract microRNAs from cancer tissues. The related report by Ma et al, "Profiling and discovery of novel miRNAs from formalin-fixed paraffin-embedded melanoma and nodal specimens," appears in the September 2009 issue of the Journal of Molecular Diagnostics.

28 Aug 2009

Importance of increased funding for molecular diagnostics

On July 9, 2009, the Society for Women’s Health Research convened experts on Capitol Hill to educate lawmakers on the importance of increased funding for new medical tests, called molecular diagnostics.

6 Aug 2009

Measuring fragile X mental retardation

Researchers from the University of California, Davis have developed a specific and quantitative means of measuring levels of the fragile X mental retardation 1 (FMR1) protein (FMRP), which is mutated in fragile X syndrome. The related report by Iwahashi et al, "A quantitative ELISA assay for the fragile X mental retardation 1 protein," appears in the July 2009 issue of the Journal of Molecular Diagnostics.

24 Jun 2009

Advances in cystic fibrosis genetic testing

San Juan Capistrano, CA and Chantilly, VA –Three reports describing advances in cystic fibrosis genetic testing appear in the May 2009 issue of The Journal of Molecular Diagnostics .

27 Apr 2009